Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study

Arthritis Care and Research

Volumn 65, Issue 4, 2013, Pages 578-584

  Kim, Seoyoung C ^a   Newcomb, Craig ^b   Margolis, David ^b   Roy, Jason ^b   Hennessy, Sean ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL;

ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; GOUT; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAID; POPULATION RESEARCH; RISK FACTOR; SEVERE CUTANEOUS ADVERSE REACTION; TREATMENT OUTCOME;

EID: 84875748061     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21817     Document Type: Article

References (39)

1. Chan HL, Ku G, Khoo OT,. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med 1977; 7: 518-22.
2. McInnes GT, Lawson DH, Jick H,. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40: 245-9.
3. Singer JZ, Wallace SL,. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-7.
4. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al, for the EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
5. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
6. Arellano F, Sacristan JA,. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 337-43.
7. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-9.
8. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al, for the JSAR Research Group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-22.
9. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-9.
10. Clark W, Hulbert M,. Research issues: dually eligible Medicare and Medicaid beneficiaries, challenges and opportunities. Health Care Financ Rev 1998; 20: 1-10.
11. Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB,. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 2007; 45: 1216-20.
12. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Stolley PD, et al. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991; 10: 565-76.
13. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-7.
14. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, et al. A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991; 127: 831-8.
15. Schneider G, Kachroo S, Jones N, Crean S, Avetisyan R, Reynolds M,. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: erythema multiforme major/minor/not otherwise specified, Stevens-Johnson syndrome, or toxic epidermal necrolysis report. 2010. URL: http://www.mini-sentinel.org/work-products/HealthOutcomes/ Mini-Sentinel-HOI-Evidence-Review-Erythema-Multiforme-Report.pdf.
16. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
17. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ,. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64.
18. Schneeweiss S,. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-68.
19. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
20. D'Agostino RB Jr., Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81.
21. Cox D,. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
22. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
23. Fritsch P,. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome. Eur J Dermatol 2008; 18: 216-7.
24. Grayson PC, Kim SY, LaValley M, Choi HK,. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-10.
25. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA,. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-92.
26. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA,. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-80.
27. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-7.
28. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis salt-sensitivity. Hypertension 2002; 40: 355-60.
29. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-6.
30. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002; 283: F1105-10.
31. Feig DI, Soletsky B, Johnson RJ,. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300: 924-32.
32. Strom B,. Overview of automated databases in pharmacoepidemiology. In:, Strom B, Kimmel S, editors. Textbook of pharmacoepidemiology. Chichester (UK): John Wiley & Sons; 2006. p. 167-71.
33. Dincer HE, Dincer AP, Levinson DJ,. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 2002; 69: 594-608.
34. Sloan RW,. Hyperuricemia and gout. J Fam Pract 1982; 14: 923-6.
35. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH,. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis 2005; 46: 225-32.
36. Chan SH, Tan T,. HLA and allopurinol drug eruption. Dermatologica 1989; 179: 32-3.
37. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 3567-72.
38. Chung WH, Hung SI, Chen YT,. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-23.
39. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al, for the RegiSCAR Study Group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.